Meadowsweet Safety: Who the Research Raises Concerns For
Most herbal teas need a paragraph of general caution. Meadowsweet needs a whole page, and for one specific reason: it delivers salicylates. Everything on this page follows from that single chemical fact. If you have read Meadowsweet, Salicylates and the Aspirin Story, you already know the mechanism; this page sets out the groups for whom the research raises concerns.
Two framing points before the list. First, meadowsweet is not a dangerous plant in ordinary use by ordinary adults — it is a traditional European tea with a long record and no reputation for poisoning anyone. Second, its risks are concentrated in specific groups, and for a couple of those groups the potential harm is serious rather than theoretical. That combination — broadly benign, sharply contraindicated — is exactly the shape that gets people into trouble, because "it is just a herbal tea" is true for most readers and dangerously wrong for a few.
Table of Contents
- Why the Cautions Exist
- Salicylate Sensitivity and Aspirin Allergy
- Aspirin-Sensitive Asthma
- Children, Teenagers and Reye's Syndrome
- Anticoagulants and Antiplatelets
- Active Peptic Ulcer and Bleeding Risk
- Pregnancy and Breastfeeding
- Other Cautions Worth Knowing
- Rosaceae and Plant-Family Allergy
- The Unstandardised Dose Problem
- Overstated Cautions — and One People Get Backwards
- Key Research Papers
- Connections
- Featured Videos
Why the Cautions Exist
Meadowsweet's flowering tops contain salicylate glycosides (monotropitin, spiraein), salicylaldehyde, methyl salicylate and a little free salicylic acid. Once hydrolysed — largely by gut bacteria — and metabolised, what circulates is salicylate. It is the same anion your body deals with after taking aspirin, arriving more slowly, more variably, at a lower and unknown dose, and without an acetyl group.
That last point cuts both ways, and getting it right is the whole art of reading this page:
- No acetylation means the aspirin-specific harms are weaker. The irreversible platelet inhibition and the potent cyclooxygenase-1 (COX-1) blockade that drives gastric injury both depend on acetylation. Meadowsweet cannot do those things well. This is the basis of its gentler reputation, and it is chemically legitimate.
- Salicylate itself is what several of the serious reactions respond to. Salicylate sensitivity, aspirin-exacerbated respiratory disease and the Reye's syndrome association are reactions to salicylate exposure. They do not require acetylation. This is why "it is not really aspirin" is not a safety exemption.
So the accurate summary is neither "exactly like aspirin" nor "only a tea." It is: the salicylate-driven concerns apply in full; the acetylation-driven risks apply in weakened and uncertain form.
Salicylate Sensitivity and Aspirin Allergy
This is the clearest contraindication on the page.
For people who have reacted to aspirin or another salicylate — hives, facial or lip swelling, flushing, wheeze, nasal congestion, abdominal cramping, or anything resembling anaphylaxis — meadowsweet is a fresh salicylate exposure. The reaction is to salicylate, and meadowsweet supplies salicylate. The fact that it arrives as a plant glycoside rather than a tablet does not make the reactive molecule different.
Points people get wrong here:
- Most "aspirin allergy" is not true immune allergy. Reactions to nonsteroidal anti-inflammatory drugs (NSAIDs) are frequently pharmacological — driven by COX inhibition shifting arachidonic acid metabolism — rather than immunoglobulin E-mediated. That distinction matters for a clinician choosing an alternative, but it does not change the concern here. Both mechanisms respond to salicylate.
- A previous mild reaction does not predict a mild next one. Nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity reactions are not reliably graded, which is why the professional guidelines are conservative about re-exposure.
- "Natural" does not attenuate it. A dose that cannot be measured turns a cup of tea into an uncontrolled re-exposure to a compound the person reacts to.
Tier: established — classification and management guidelines for nonsteroidal anti-inflammatory drug hypersensitivity are well developed, and the salicylate content of meadowsweet is analytically documented.
Aspirin-Sensitive Asthma
This is the caution most often skipped in herbal write-ups, and it is the one where a reaction can be severe.
Aspirin-exacerbated respiratory disease (AERD) — also called nonsteroidal anti-inflammatory drug-exacerbated respiratory disease, and historically Samter's triad — is a distinct condition combining asthma, chronic rhinosinusitis with nasal polyps, and reactions to aspirin and other cyclooxygenase-1-inhibiting drugs. The mechanism is not allergy: cyclooxygenase-1 inhibition diverts arachidonic acid down the 5-lipoxygenase pathway, producing a surge of cysteinyl leukotrienes that triggers bronchoconstriction and severe upper-airway symptoms. Reactions can be dramatic and have caused fatalities.
It is not rare. A 2015 meta-analysis of 27 studies (Rajan and colleagues) put AERD at roughly 7% of adults with asthma (7.15%), about twice that in severe asthma (14.89%), 9.69% among people with nasal polyps and 8.7% among people with chronic rhinosinusitis. So among readers with asthma, a meaningful minority is at risk.
What this means for meadowsweet, reasoning from the drug evidence:
- Asthma with nasal polyps, or asthma with a known aspirin/nonsteroidal anti-inflammatory drug reaction, is the group the AERD evidence points to most directly; for them meadowsweet adds a salicylate exposure.
- People with asthma who have never taken a nonsteroidal anti-inflammatory drug do not know whether they have AERD, and an unmeasured salicylate dose is an uncontrolled way to find out.
- The dose question is genuinely uncertain here. AERD reactions are dose-related and typically provoked by therapeutic drug doses, so a weak herbal infusion may well be below anyone's threshold. Nobody knows, because neither the herb's salicylate content nor any individual's threshold is measured. The potential outcome is a severe asthma attack, and the risk is unquantified.
Tier: established for the drug reaction (well-documented mechanism, prevalence meta-analysis, clinical guidelines); inferred for the herb. Background on the condition sits on Asthma.
Children, Teenagers and Reye's Syndrome
The research raises its most serious concern for children and teenagers — above all during a viral illness such as influenza or chickenpox.
Reye's syndrome is a rare but often fatal illness of acute encephalopathy with fatty degeneration of the liver, described in the 1960s and occurring predominantly in children recovering from a viral infection. Epidemiological studies in the late 1970s and early 1980s linked it to salicylate exposure during that illness. Public health warnings against giving aspirin to children followed in the early 1980s, and reported cases in the United States and United Kingdom fell dramatically afterwards — one of the clearer natural experiments in paediatric drug safety. US national surveillance recorded 1,207 cases in people under 18 from December 1980 through November 1997: reported cases in children peaked at 555 in 1980 and were no more than 36 a year from 1987 on; 82% of the patients had detectable salicylate in their blood, and 31% of all cases died (Belay 1999). The association is with salicylates, not specifically with acetylsalicylic acid, which is why paediatric guidance covers salicylate-containing products generally.
Three honest qualifications, none of which remove the concern:
- No case of Reye's syndrome has been attributed to meadowsweet. The caution is precautionary and mechanistic, extrapolated from salicylate class safety.
- The dose in a tea is probably far below aspirin's paediatric antipyretic dose. Probably. Unmeasured.
- The tradition directly contradicts this. Meadowsweet was historically given to children for stomach upsets and fever, and that use is still repeated in herbal books. Here centuries of tradition collide with a documented drug-safety association carrying a high fatality rate (31% of US cases in the surveillance data above).
The overlap is uncomfortably precise: meadowsweet's classic traditional use is fever in a viral illness, and that is exactly the Reye's scenario. The fever medicines used for children that are not salicylates are paracetamol (acetaminophen) and ibuprofen, dosed by weight.
Tier: established epidemiological association for salicylates; precautionary extrapolation for meadowsweet.
Anticoagulants and Antiplatelets
The concern is real but indirect. Salicylate is highly protein-bound and can push warfarin off the blood protein albumin; warfarin is monitored by international normalized ratio (INR) blood tests because small changes matter; and the conventional stop for salicylate-containing herbs before surgery is one to two weeks. Here the honest answer is more nuanced than the standard warning, and the nuance is worth having.
The standard warning in herbal references is against combining meadowsweet with warfarin, direct oral anticoagulants, clopidogrel or aspirin. The mechanistic case is weaker than usually implied, and these are the reasons the caution still stands:
- Non-acetylated salicylates barely affect platelets. Meadowsweet's salicylates are not acetylated, so the potent irreversible platelet inhibition that makes aspirin a bleeding risk is largely absent. Salsalate and other non-acetylated salicylate drugs are recognised as having minimal antiplatelet effect. On that reasoning alone, a meadowsweet interaction would be expected to be small.
- But salicylate has other pathways to bleeding risk. Salicylate is highly protein-bound and can displace warfarin from albumin; high salicylate doses can interfere with haemostasis independently of platelets; and polyphenol-rich extracts show antiplatelet activity in vitro, though the human relevance of that is unclear.
- The dose is unmeasurable and the consequence of being wrong is a bleed. This, rather than the mechanism, is the decisive argument. Anticoagulation is a narrow-margin business — warfarin in particular is monitored by international normalized ratio (INR) precisely because small perturbations matter. Adding an unquantified salicylate exposure to a carefully titrated anticoagulant means an unquantified bleeding risk for a tea with no proven benefit.
For people on warfarin, an unexplained change in international normalized ratio readings is the measurable sign of such an interaction. Before planned surgery or dental extraction, the conventional stop for salicylate-containing herbs is one to two weeks.
Tier: theoretical interaction with a strong precautionary rationale; not a documented meadowsweet-specific interaction. Related reading: Aspirin: Bleeding Risks and Cautions.
Active Peptic Ulcer and Bleeding Risk
Active peptic ulcer disease is a concern despite the traditional use. This is the one caution on the page that runs against the plant's most interesting property, so it needs explaining.
Meadowsweet is traditionally used for stomach complaints, and animal work does show gastroprotective activity — the 2018 Journal of Ethnopharmacology study is genuine and is discussed fully on Meadowsweet for Digestion and Stomach Comfort. The reasons the concern stands in an actual ulcer:
- The gastroprotection is preclinical. Rodent gastric-lesion models are not human peptic ulcers, and there is no human trial. A rodent result says little about an active human ulcer.
- The downside is asymmetric. If the herb is neutral there is no gain; if it is mildly irritating the risk is a bleed or perforation.
- Tannins can irritate. Meadowsweet is markedly astringent, and concentrated tannins provoke nausea and gastric discomfort in some people, particularly on an empty stomach.
- Ulcers have treatable causes. Helicobacter pylori eradication and acid suppression heal ulcers reliably. Substituting tea means an untreated ulcer, which is the real harm here — not the tea's direct effect. See Peptic Ulcer Disease.
The same reasoning extends to anyone with a history of gastrointestinal bleeding, oesophageal varices, or a bleeding disorder such as haemophilia or von Willebrand disease, and to anyone with a low platelet count.
Warning signs that hospitals treat as urgent or investigate promptly: vomiting blood or coffee-ground material, black tarry stools, unexplained weight loss, difficulty swallowing, persistent vomiting, or new severe upper abdominal pain.
Pregnancy and Breastfeeding
Two independent concerns, either sufficient on its own.
First, salicylates are generally avoided in pregnancy outside specific medical indications, and nonsteroidal anti-inflammatory drugs are contraindicated in the third trimester because of effects on the fetal ductus arteriosus and on labour. Where low-dose aspirin is used in pregnancy — for pre-eclampsia prevention, for example — it is prescribed and monitored deliberately, at a known dose, which is the opposite of an unstandardised tea.
Second, and more simply, there is no safety data for meadowsweet in pregnancy or lactation. No trials, no registry data, no systematic case series. "No known harm" here means nobody has looked, which is not reassurance.
Salicylates also pass into breast milk. Given the Reye's syndrome association in children, an unmeasured salicylate reaching a nursing infant is a risk with no proven benefit on the other side.
Tier: established for salicylate drugs in pregnancy; absence of data for meadowsweet.
Other Cautions Worth Knowing
- Stacking on aspirin or nonsteroidal anti-inflammatory drugs. For people who already take aspirin, ibuprofen, naproxen or diclofenac, meadowsweet adds an unknown salicylate dose to a known one. There is no known benefit to this, and it makes total exposure unmeasurable.
- Kidney disease. Salicylates and nonsteroidal anti-inflammatory drugs are cleared renally and can affect renal blood flow. In significant chronic kidney disease, an unmeasured salicylate adds to that load. See Aspirin and the Kidneys.
- Liver disease. Salicylate is hepatically metabolised, and impaired liver function alters handling of it, so the same concern applies.
- Gout and uric acid. Salicylates have a genuinely dose-dependent, biphasic effect on uric acid handling — low doses tend to reduce urate excretion (raising serum urate) while high doses are uricosuric. Where an unmeasured herbal dose falls on that curve is unknown, so there is no basis for assuming it helps in gout, and some reason for concern.
- Methotrexate. Salicylates can reduce methotrexate clearance and raise its toxicity; the interaction is documented for salicylate drugs and has not been studied for meadowsweet.
- Surgery and dental procedures. The conventional stop for salicylate-containing herbs is one to two weeks beforehand.
- Iron absorption. Tannin-rich teas reduce non-haem iron absorption when drunk with meals. In iron-deficiency anaemia this matters most; the effect applies to tea drunk with meals, not between them.
- Correct identification. Wild-gathered meadowsweet grows in damp ground alongside plants that are not benign, and confident plant identification is a skill, not a guess.
- Duration. Traditional use is short-term and symptomatic. Continuous long-term daily use has never been studied, and there is no basis for calling it safe indefinitely.
Rosaceae and Plant-Family Allergy
Meadowsweet is a member of Rosaceae, the rose family — the same family as apple, pear, cherry, plum, peach, apricot, almond, strawberry, raspberry and blackberry. Two implications, both modest.
First, a general one: people with pollen-food allergy syndrome frequently react to Rosaceae fruits, driven by allergens including profilins and lipid-transfer proteins. Whether that translates to a reaction to a Rosaceae flower infusion is not established — there is no documented pattern of meadowsweet allergy in people allergic to Rosaceae fruits, and the allergens involved are not necessarily shared or heat-stable in a tea. It is a point worth knowing, not evidence of a risk for most people.
Second, a practical one: for people with significant Rosaceae fruit allergy, or a history of anaphylaxis to any plant food, a first cup of any new botanical carries the same unknown as any new plant food. That is a generic point rather than a meadowsweet-specific warning.
Tier: established plant taxonomy; speculative cross-reactivity. Flagged for completeness, weighted accordingly.
The Unstandardised Dose Problem
Underneath every caution above sits one structural problem: no one can know how much salicylate a cup delivers.
Every stage adds uncertainty. Salicylate content varies by plant part, population, harvest timing and growing conditions. Salicylaldehyde and methyl salicylate are volatile and are lost during drying, storage and uncovered brewing. Whether the cup is covered changes the result. And because the glycosides need bacterial hydrolysis to release their salicylate, the delivered dose depends on each person's gut flora. No meadowsweet tea on the market is standardised to a salicylate content the way a willow bark extract can be standardised to salicin.
One measured example of that variation: a Lithuanian study of meadowsweet flowers from five habitats found 1.2 to 2 times more volatile oil at early flowering than at late flowering. Salicylaldehyde and methyl salicylate were the main salicylates in the oil at both stages, and they moved in opposite directions — when one rose, the other fell (r = −0.94) (Ložienė 2023).
Confident milligram figures do not hold up. Published analyses vary widely, tea products are not labelled for salicylate, and any single number quoted as "the" salicylate content of a cup of meadowsweet tea is at best one measurement of one batch.
Two consequences follow:
- It cannot be titrated — it does not work as a substitute for a measured painkiller dose, and "one more cup" does not deliver a known stronger effect.
- It cannot be ruled out either — for someone in whom a salicylate is contraindicated, an unmeasured salicylate is not a safe version of it.
Overstated Cautions — and One People Get Backwards
Balance requires saying which warnings are overstated.
The coumarin claim is backwards. Meadowsweet's constituent list often includes coumarins, and this gets cited as evidence that the herb "thins the blood." That reasoning is wrong. Plain coumarin is a fragrant plant compound — the smell of new-mown hay — and it is not an anticoagulant. The anticoagulant is dicoumarol, which forms when coumarin-containing sweet clover spoils and moulds; that discovery led to warfarin. Coumarin in an intact, properly dried herb is not dicoumarol and does not thin blood. The plausible bleeding-related concern with meadowsweet is the salicylate one discussed above — getting the mechanism right matters, because a wrong mechanism produces wrong conclusions about what else is risky.
Meadowsweet is not a toxic plant. It has no reputation as a poisonous species, no characteristic toxidrome, and no history of serious harm in ordinary culinary and traditional use — it was used to flavour mead and beer, and to scent floors. For a healthy adult not in any group above, a cup or two of meadowsweet tea is a low-risk thing to drink.
The stomach caution is a genuine judgement call, not settled fact. This page lists active ulcer disease as a concern. That concern is precautionary and follows from the absence of human evidence rather than from any demonstrated harm. Somebody could reasonably argue the tradition and the animal data the other way. What nobody can honestly say is that the human evidence settles it, because there is none.
Key Research Papers
PubMed records and topic searches with evidence tiers. Note how many of the strongest citations concern salicylate drugs rather than meadowsweet — that is the accurate picture, and it is why this page reasons by extrapolation and says so.
- Reye RD, Morgan G, Baral J. "Encephalopathy and fatty degeneration of the viscera. A disease entity in childhood." Lancet, 1963;2(7311):749-752. The original description of the syndrome. Tier: original clinical description. — PubMed PMID: 14055046
- Epidemiological studies linking salicylate use to Reye's syndrome, and the fall in cases after public health warnings. Including the surveillance data showing US cases declining sharply through the 1980s and 1990s. Tier: epidemiological, strong. — Search PubMed
- Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB. "Reye's syndrome in the United States from 1981 through 1997." New England Journal of Medicine, 1999;340(18):1377-1382. National surveillance data: 1,207 cases, the 1980 peak of 555 and a 31% case fatality rate. Tier: epidemiological surveillance. — PubMed PMID: 10228187
- Reviews of the aspirin–Reye's syndrome evidence. Assessments of how strong the association is and how it shaped paediatric salicylate guidance. Tier: review of epidemiological evidence. — Search PubMed
- Rajan JP, Wineinger NE, Stevenson DD, White AA. "Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature." Journal of Allergy and Clinical Immunology, 2015;135(3):676-681. The source of the roughly 7% figure quoted above, with 14.89% in severe asthma. Tier: meta-analysis of prevalence studies. — PubMed PMID: 25282015
- Mechanistic and clinical literature on AERD. COX-1 inhibition, cysteinyl-leukotriene overproduction, and the asthma–nasal-polyp–NSAID-reaction triad. Tier: established mechanism plus clinical studies. — Search PubMed
- Guidelines on the classification, diagnosis and management of NSAID hypersensitivity. Including the distinction between true allergy and pharmacological cross-intolerance. Tier: expert guideline. — Search PubMed
- Comparative literature on non-acetylated salicylates. Salsalate and relatives — less gastric toxicity, minimal platelet effect. The evidence behind this page's "weakened but uncertain" framing. Tier: clinical pharmacology of drugs. — Search PubMed
- Salicylate–warfarin interaction literature, including protein-binding displacement. The mechanistic basis for the anticoagulant caution. Tier: pharmacokinetic and clinical (drugs). — Search PubMed
- Salicylate–methotrexate interaction literature. Reduced methotrexate clearance and increased toxicity. Tier: pharmacokinetic and clinical (drugs). — Search PubMed
- Literature on the biphasic, dose-dependent effect of salicylates on uric acid handling. Why the gout caution is genuinely uncertain rather than merely conventional. Tier: established human pharmacology. — Search PubMed
- NSAIDs and salicylates in pregnancy. Third-trimester contraindication, ductus arteriosus effects, and the separate deliberate use of prescribed low-dose aspirin. Tier: established clinical evidence. — Search PubMed
- Samardžić S, Arsenijević J, Božić D, Milenković M, Tešević V, Maksimović Z. "Antioxidant, anti-inflammatory and gastroprotective activity of Filipendula ulmaria (L.) Maxim. and Filipendula vulgaris Moench." Journal of Ethnopharmacology, 2018;213:132-137. Gastric injury in rats, plus laboratory assays. Included here because it is the evidence against part of this page's caution, and readers should see both sides. Tier: preliminary (animal). — PubMed PMID: 29132911
- Savina T, Lisun V, Feduraev P, Skrypnik L. "Variation in Phenolic Compounds, Antioxidant and Antibacterial Activities of Extracts from Different Plant Organs of Meadowsweet (Filipendula ulmaria (L.) Maxim.)." Molecules, 2023;28(8):3512. The analytical evidence that the dose in a tea cannot be known. Tier: analytical. — PubMed PMID: 37110746
- Ložienė K, Būdienė J, Vaitiekūnaitė U, Pašakinskienė I. "Variations in Yield, Essential Oil, and Salicylates of Filipendula ulmaria Inflorescences at Different Blooming Stages." Plants (Basel), 2023;12(2):300. Salicylate-bearing oil varies with flowering stage. Tier: analytical. — PubMed PMID: 36679011
- Dicoumarol, spoiled sweet clover and the origin of warfarin. The history that shows plain plant coumarin is not an anticoagulant. Tier: established history and pharmacology. — Search PubMed
- Rosaceae fruit allergy, profilins and lipid-transfer proteins. Background for the plant-family point, which remains speculative for meadowsweet. Tier: established for fruits; speculative for this herb. — Search PubMed
External Resources
- PubMed — the database behind the searches above.
- NIH National Center for Complementary and Integrative Health — herb safety summaries and interaction warnings.
- MedlinePlus — plain-language drug and supplement information.
- DailyMed — official US prescribing information, useful for checking a medication's own salicylate and NSAID warnings.
- European Medicines Agency — the traditional-use regulatory category that meadowsweet products fall under in Europe.
Connections
- All Herbs
- Meadowsweet
- Meadowsweet Benefits Hub
- Meadowsweet and the Aspirin Story
- Meadowsweet for Digestion
- Meadowsweet for Joint Pain and Fever
- Willow Bark
- Aspirin
- Aspirin Side Effects
- Aspirin Bleeding Risks
- Aspirin and the Kidneys
- Asthma
- Peptic Ulcer Disease
- Gastritis
- Gout
- Rheumatoid Arthritis
- Marshmallow Root
- Slippery Elm
- Chamomile
Safety and disclaimer. To summarise the whole page: avoid meadowsweet if you are sensitive to aspirin or salicylates, if you have aspirin-sensitive asthma or asthma with nasal polyps, if you are pregnant or breastfeeding, or if you are a child or teenager — especially during a viral illness. Do not combine it with anticoagulants, antiplatelets, methotrexate or other nonsteroidal anti-inflammatory drugs without your prescriber's agreement, and avoid it in active peptic ulcer disease or with any bleeding disorder. Because the salicylate dose in a tea cannot be measured, it cannot be titrated and it cannot be assumed to be negligible. This page is educational information, not medical advice, and it is not a reason to change or stop any prescribed medicine. Talk to your doctor or pharmacist about your own situation.